Evidence map›Paper›PMID 31412903›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer.

Huan Yan, Hong Li, Maria A Silva, Yichun Guan, Li Yang, Linlin Zhu, Zhan Zhang, Genxia Li, Chenchen Ren

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. The Role of EMT-Related lncRNAs in Ovarian Cancer.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Huan YanDepartment of Obstetrics and Gynecology, the Third Affiliated Hospital of Zhengzhou University, No. 7 Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China.
Hong LiDepartment of Obstetrics and Gynecology, the Third Affiliated Hospital of Zhengzhou University, No. 7 Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China. hongli_131@yahoo.com.ORCID http://orcid.org/0000-0002-6406-0139
Maria A SilvaDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Yichun GuanCenter for Reproductive Medicine, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Li YangDepartment of Obstetrics and Gynecology, the Third Affiliated Hospital of Zhengzhou University, No. 7 Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China.
Linlin ZhuCollaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan, People's Republic of China.
Zhan ZhangDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Genxia LiDepartment of Obstetrics and Gynecology, the Third Affiliated Hospital of Zhengzhou University, No. 7 Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China.
Chenchen RenDepartment of Obstetrics and Gynecology, the Third Affiliated Hospital of Zhengzhou University, No. 7 Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China.
Third Affiliated Hospital of Zhengzhou University · CNUniversity of Tennessee Health Science Center · US

Funding

Science and Technology Department of Henan Province (CN) 162102310131
6 · The paper itself

Abstract

backgroundLong noncoding RNAs (lncRNAs) have been reported to be associated with the proliferation of several cancer cells. The aim of this study was to investigate the role of FLVCR1-AS1 in ovarian serous cancer (OSC).

methodsFLVCR1-AS1 expression was determined in human OSC tissues, serums and cell lines. The role of FLVCR1-AS1 knockdown or overexpression on OSC cell growth, migration, invasion, apoptosis and epithelial to mesenchymal transition (EMT) were evaluated in vitro using CCK8, colony formation assay, wound healing assay, transwell assay and western blot assay. Besides, luciferase reporter assays were performed to identify interactions among FLVCR1-AS1 and its target genes. Moreover, the in vivo effects were investigated using immunocompromised NSG female mice.

resultsIn this study, FLVCR1-AS1 expression was upregulated in OSC tissues, serums, and cells. Knockdown FLVCR1-AS1 decreased cell growth, migration, invasion, and EMT, as well as increased apoptosis in OSC cells, whereas, overexpression of FLVCR1-AS1 increased cell proliferation, migration, invasion, and EMT, and decreased apoptosis of OSC cells. Besides, FLVCR1-AS1 directly bound to miR-513 and downregulated its expression. Moreover, FLVCR1-AS1 reversed the effect of miR-513 on the OSC cell growth, which might be associated with the role of YAP1. Furthermore, in terms of mechanism, FLVCR1-AS1 promoted EMT in OSC cells. Finally, mice models further confirmed that knockdown FLVCR1-AS1 distinctly suppressed cell growth and EMT in vivo.

conclusionTaken together, FLVCR1-AS1 mediated miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in OSC cells.

Indexed as

Signal TransductionAdaptor Proteins, Signal TransducingAnimalsApoptosisBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMembrane Transport ProteinsAdaptor Proteins, Signal TransducingBiomarkers, TumorFLVCR1 protein, humanMembrane Transport ProteinsMicroRNAsMIRN513A1 microRNA, humanReceptors, VirusRNA, Long NoncodingTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsEMTFLVCR1-AS1LncRNAmiR-513Ovarian serous cancerYAP1

Identifiers

PMID31412903
PMCPMC6694549
OpenAlexW2967230599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.